Studies have shown that exogenous administration of recombinant human IGF-I (51, 52) and IGF-I/IGFBP-3 complex (53–55) improved insulin sensitivity and decreased insulin requirements in both T1D and T2D patients. This evidence concerns the gene IGF1 and type 2 diabetes mellitus.